Trial Search Results

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

The purpose of this prospective study is to verify whether exhaustive prognostic collection of clinical data can achieve more accurate information for prognosis and treatment strategies for Peripheral T-Cell Lymphoma (PTCL). To this end, clinical information from patients diagnosed with PTCL will be collected and compared. This comparison will be used to determine if there are common factors among patients, with similarly developing forms of the disease, which may give an indication of the evolution of the disease. Additionally, there will be a central review of the pathology from the patient's biopsy which was collected at the time of his/her diagnosis. This study may help doctors in the future predict the prognosis of newly diagnosed patients with more frequent subtypes of PTCL, and better define clinical characteristics and outcome of more uncommon subtypes.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Associazione Angela Serra per la ricerca sul cancro

Collaborator: INTERNATIONAL T-CELL NON-HODGKIN'S LYMPHOMA STUDY GROUP

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell
   lymphoma:

      - Peripheral T-cell lymphoma unspecified;

      - Peripheral T-cell lymphoma, lymphoepithelioid variant;

      - Peripheral T-cell lymphoma, T-zone variant ;

      - Peripheral T-cell lymphoma, parafollicular variant ;

      - Angioimmunoblastic T-cell lymphoma;

      - Nasal NK/T-cell lymphoma;

      - NK/T-cell lymphoma, nasal time;

      - Anaplastic large-cell lymphoma, T/null cell, ALK+, primary systemic type

      - Anaplastic large-cell lymphoma, T/null cell, ALK-, primary systemic type

      - Anaplastic large cell lymphoma, small cell variant, ALK+

      - Anaplastic large cell lymphoma, lymphohistiocytic variant, ALK+

      - Enteropathy- type T-cell lymphoma;

      - Hepatosplenic T-cell lymphoma;

      - Peripheral gamma-delta T-cell lymphoma;

      - Subcutaneous panniculitis-like T-cell lymphoma;

      - Unclassifiable peripheral T-cell Lymphoma

      - Unclassifiable NK-cell lymphoma

   2. Age over 18

   3. Tissue biopsies adequate for diagnosis and classification and available for
   centralized review

   4. Clinical data including baseline information on disease localization and laboratory
   parameters at staging, features of treatment adopted and assurance of follow-up
   updating for at least 5 years are requested

   5. Written informed consent

Exclusion Criteria:

   1. Age < 18

   2. Diagnosis of T-cell or NK-cell leukemia or proliferation and other than mature types
   including:

      - Adult T-cell leukemia/lymphoma;

      - Blastic NK-cell leukemia/lymphoma;

      - Aggressive NK-cell leukemia

      - T-cell large granular lymphocytic leukemia

      - T-cell large granular lymphocytic proliferation

      - NK-cell large granular lymphocytic proliferation

      - T-cell prolymphocytic leukemia

      - Precursor T-cell lymphoblastic leukemia/lymphoma

      - Mycosis fungoides;

      - S├ęzary syndrome;

      - Primary cutaneous ALCL

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting